Venture capital firm's Chinese investment to be reviewed by U.S. Treasury; Small-scale M&A on the rise despite trade tensions, sluggish growth; and U.S. Congressmen urge delisting of 25 Chinese groups from U.S. exchanges.
The Cyberspace Administration clarifies its approach to the export of personal and important information out of China; UK weighs whether to include China in foreign influence disclosure rules; and Burberry wins online trademark infringement suit.
Total asset requirement is relaxed for Hong Kong and Macao insurance company investments / CLP Reference: 3910/25.02.26 ; Issued: 2025-02-26 ; Effective: 2025-03-01
China’s draft pharmaceutical trial rules aim to balance innovation with drug availability; CAC issues first rules to regulate facial recognition technology; and UBS becomes the 5th wholly foreign-owned securities firm in China.
Trump signs memorandum to restrict investments that do not serve American interests; A Jiangsu court ruled that investments in overseas crypto projects are not protected under Chinese law; and Chinese companies raise funds in hope of easing of regulations against private enterprises
In 2024, the U.S. continued placing wide-ranging restrictions on Chinese interests. What made that year different was the impact those restrictions have on third countries. Charles Wu of Clyde & Co reviews the legislative changes, and offers practical insights into their potential impact with a focus on third countries, and the path forward in 2025
The final rules of reverse CFIUS differ from the draft version; China changes its foreign investment rules to attract more long-term and high-quality investments; and Chinese data center company raises $1 billion from U.S. PE investors.
